2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.
Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses a phase II trial that examined the oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor PD 0332991 (991) as a first-line therapy for women with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
In general, CDKs are regulated by cyclins and facilitate the cell cycle. The rationale for the trial was based on the observed overproduction of cyclin D in patients with ER-positive breast cancer, Tripathy explains. In general, cyclin D is encoded by the CCND1 gene and interacts with CDK 4 and 6 to moderate cell cycle progression.
In the trial, 165 patients were randomized 1:1 to receive letrozole alone or in combination with PD 0332991. Patients were further stratified into two parts based on CCND1 amplification and/or a loss of p16 expression, both indicators of cyclin D abnormality.
The addition of PD 0332991 to letrozole resulted in improved progression-free survival (PFS) between all subgroups of the trial. The median PFS benefit for the combination was 26.1 months compared to 7.5 months for letrozole alone (HR = 0.37; P < .001).
Tripathy notes that toxicities with PD 0332991 did not appear to be significantly greater. The most common adverse event was uncomplicated neutropenia, which was easily managed in the trial.
A randomized phase III trial examining PD 0332991 is scheduled.